Workflow
基因数据资产化
icon
Search documents
华大基因CEO赵立见:从企业自主创新跃升至顶层设计 政策红利催化基因产业升级
Mei Ri Jing Ji Xin Wen· 2025-11-12 14:10
Core Insights - The Guangzhou government has introduced a policy to accelerate the development of future industries, designating the cell and gene industry as one of the six key sectors, which is seen as a significant boost for the industry [2][3] - The CEO of BGI Genomics, Zhao Lijian, emphasizes that this policy elevates the industry from enterprise-driven innovation to government-level design, providing essential support for innovation and development in the biological sector [2][4] - BGI Genomics is leveraging local policies and resources to expand its business, including a free genetic screening program for pregnant women in Guangzhou, supported by the local government [3][5] Industry Development - The new policy is expected to enhance the transformation of new technologies in the biological sector, with BGI Genomics planning to conduct clinical trials for new diagnostic technologies in Guangzhou [4] - Despite the widespread application of genetic testing, high costs remain a barrier to accessibility; however, BGI Genomics aims to reduce costs through self-sufficiency in technology and materials [4][6] - The integration of genetic testing into medical insurance is viewed as a long-term opportunity for the industry, despite potential short-term revenue pressures [6][7] Data Assetization - The value of genetic data is increasingly recognized, with a focus on ensuring data security and compliance during the assetization process [7] - BGI Genomics is collaborating with Shenzhen Data Exchange to ensure strict data asset certification, emphasizing the importance of privacy protection [7] - The company aims to utilize genetic data to support the development of innovative drugs for rare diseases, potentially reducing treatment costs and improving early diagnosis [7][8] Future Outlook - Zhao Lijian expresses confidence in the future of the gene industry, anticipating new opportunities driven by policy support, technological innovation, and the increasing value of data [8]
专访华大基因CEO赵立见:从企业自主跃升至顶层设计, 政策红利催化基因产业升级
Sou Hu Cai Jing· 2025-11-11 10:20
Core Viewpoint - The article discusses the significant impact of Guangzhou's policy on the development of the gene industry, highlighting the role of BGI Genomics in advancing gene testing accessibility and innovation in the sector [1][3]. Policy Impact - Guangzhou has prioritized the cell and gene industry as one of its six future industries, which is seen as a crucial step for the sector's growth [3]. - The policy elevates the industry from enterprise-led innovation to government-level design, providing a supportive framework for innovation and development [3][4]. - The implementation of this policy is viewed as a critical move for the localization of national macro policies [3]. Company Strategy - BGI Genomics is leveraging local policy advantages to expand its business, including establishing subsidiaries and developing domestic testing platforms [3][4]. - The company aims to make gene testing accessible to everyone by optimizing costs and enhancing technology [5][7]. - BGI Genomics plans to utilize Guangzhou's rich medical resources for clinical trials and the introduction of new diagnostic technologies [4][6]. Cost and Accessibility - High costs of gene testing have been a barrier to widespread adoption, but BGI Genomics is working to reduce these costs through self-sufficiency in technology and materials [5][6]. - Government initiatives, such as free prenatal screening programs, are seen as effective pathways to increase accessibility [5][6]. - The integration of gene testing into medical insurance is expected to broaden access, despite potential short-term revenue pressures for companies [6][7]. Data Assetization - The value of gene data is increasingly recognized, with a focus on data assetization while ensuring compliance and privacy [8]. - BGI Genomics is collaborating with Shenzhen Data Exchange to ensure strict data security measures [8]. - The company envisions using gene data to support the development of innovative drugs and early screening for rare diseases, aiming to reduce treatment costs [8]. Future Outlook - The gene industry is anticipated to experience new growth opportunities due to policy support, technological advancements, and the increasing value of data [8]. - BGI Genomics is committed to enhancing its competitiveness and contributing to societal progress through accessible gene testing [8].